Results 21 to 30 of about 5,434 (169)

Poliovirus receptor CD155-targeted oncolysis of glioma [PDF]

Neuro-Oncology, 2004
Cell adhesion molecules of the immunoglobulin superfamily are aberrantly expressed in malignant glioma. Amongst these, the human poliovirus receptor CD155 provides a molecular target for therapeutic intervention with oncolytic poliovirus recombinants. Poliovirus has been genetically modified through insertion of regulatory sequences derived from human ...
Melinda K, Merrill, Guenter, Bernhardt, John H, Sampson, Carol J, Wikstrand, Darell D, Bigner, Matthias, Gromeier   +5 more
openaire   +2 more sources

Overexpression of the CD155 gene in human colorectal carcinoma [PDF]

Gut, 2001
BACKGROUND AND AIMS The Tage4 gene (tumour associated glycoprotein E4) is overexpressed in rat colon tumours and Min mouse intestinal adenomas. The rat Tage4 protein has approximately 40% identity with human CD155, a member of the immunoglobulin ...
Masson, D, Jarry, Anne, Baury, B, Blanchardie, P, Laboisse, C, Lustenberger, P, Denis, M   +6 more
openaire   +4 more sources

CD155 and Its Receptors as Targets for Cancer Therapy

International Journal of Molecular Sciences, 2023
CD155, also known as the poliovirus receptor, is an adhesion molecule often overexpressed in tumors of different origins where it promotes cell migration and proliferation. In addition to this pro-tumorigenic function, CD155 plays an immunomodulatory role during tumor progression since it is a ligand for both the activating receptor DNAM-1 and the ...
Rossella Paolini, Rosa Molfetta
openaire   +3 more sources

Receptors for hyaluronic acid and poliovirus: a combinatorial role in glioma invasion? [PDF]

PLoS ONE, 2012
BACKGROUND: CD44 has long been associated with glioma invasion while, more recently, CD155 has been implicated in playing a similar role. Notably, these two receptors have been shown closely positioned on monocytes.
Zaynah Maherally, James R Smith, Qian An, Geoffrey J Pilkington   +3 more
doaj   +1 more source

Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

Journal of Immunology Research, 2020
Purpose. The immune checkpoint inhibitor is approved for breast cancer treatment, but the low expression of PD-L1 limits the immunotherapy.
Yu-Chen Li, Quan Zhou, Qing-Kun Song, Rui-Bin Wang, Shuzhen Lyu, Xiudong Guan, Yan-Jie Zhao, Jiang-Ping Wu   +7 more
doaj   +1 more source

Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells

Beni-Suef University Journal of Basic and Applied Sciences, 2023
Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types.
Passant Essam Eldin Shibel, Eman Ahmed Abd Elmaogod   +1 more
doaj   +1 more source

Complexes of Poliovirus Serotypes with Their Common Cellular Receptor, CD155 [PDF]

Journal of Virology, 2003
ABSTRACT Structures of all three poliovirus (PV) serotypes (PV1, PV2, and PV3) complexed with their cellular receptor, PV receptor (PVR or CD155), were determined by cryoelectron microscopy. Both glycosylated and fully deglycosylated CD155 exhibited similar binding sites and orientations in the viral canyon for all three PV serotypes, showing
Yongning, He, Steffen, Mueller, Paul R, Chipman, Carol M, Bator, Xiaozhong, Peng, Valorie D, Bowman, Suchetana, Mukhopadhyay, Eckard, Wimmer, Richard J, Kuhn, Michael G, Rossmann   +9 more
openaire   +2 more sources

Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression

Scientific Reports, 2023
We aimed to compare the prognostic impacts of adenocarcinoma subtypes, programmed death-ligand I (PD-L1), and CD155 expression on patients with resected pathological stage (p-stage) I lung adenocarcinoma. In total, 353 patients with completely resected p-
Natsumasa Nishizawa, Shohei Shimajiri, Rintaro Oyama, Takehiko Manabe, Yukiko Nemoto, Hiroki Matsumiya, Yohei Honda, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka   +10 more
doaj   +1 more source

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer

Frontiers in Oncology, 2023
BackgroundImmune checkpoint inhibition, combined with novel biomarkers, may provide alternative pathways for treating chemotherapy-resistant triple-negative breast cancer (TNBC).
Neslihan Cabioglu, Aysel Bayram, Selman Emiroglu, Semen Onder, Huseyin Karatay, Huseyin Karatay, Gizem Oner, Gizem Oner, Gizem Oner, Mustafa Tukenmez, Mahmut Muslumanoglu, Abdullah Igci, Abdullah Igci, Adnan Aydiner, Pinar Saip, Ekrem Yavuz, Vahit Ozmen, Vahit Ozmen   +17 more
doaj   +1 more source

Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells.

PLoS ONE, 2013
Genotoxic stress and RAS induce the expression of CD155, a ligand for the immune receptors DNAM-1, CD96 and TIGIT. Here we show that antigen-presenting cells upregulate CD155 expression in response to Toll-like receptor activation.
Neha Kamran, Yoshimi Takai, Jun Miyoshi, Subhra K Biswas, Justin S B Wong, Stephan Gasser   +5 more
doaj   +1 more source